TELA Bio Q2 2025 Earnings Report

TELA Bio EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.18
• Beat/Miss: N/A
• One Year Ago EPS: N/A

TELA Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $20.67 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

TELA Bio Announcement Details

• Quarter: Q2 2025
• Date: 8/11/2025
• Time: After Market Closes
• Conference Call Date: Monday, August 11, 2025
• Conference Call Time: 4:30PM ET

TELA Bio (NASDAQ:TELA) is a clinical-stage regenerative medicine company focused on the development and commercialization of next‐generation biomaterial therapies designed to improve the repair of soft tissue across multiple surgical specialties. The company’s proprietary platform combines biologically derived materials with synthetic polymer reinforcement to create a family of hybrid tissue repair products that are intended to support tissue regeneration, restore functional integrity and reduce complications associated with existing repair solutions.

The company’s lead portfolio centers on the OviTex® line of soft tissue repair products. These mesh-like scaffolds utilize a unique interwoven design of decellularized ovine extracellular matrix and permanent or resorbable polymer fibers, offering strength, biocompatibility and the potential for cellular in‐growth. OviTex products are used primarily in hernia repair and abdominal wall reconstruction, with ongoing development programs targeting orthopedic soft tissue applications, sports medicine and general surgical procedures.

Founded in 2016 and headquartered in Malvern, Pennsylvania, TELA Bio completed its initial public offering in mid-2021 and has since expanded its commercial footprint across the United States and select international markets. The company leverages a direct sales force, strategic distribution partnerships and clinical collaborations to support adoption of its regenerative technologies. TELA Bio continues to advance its research pipeline through preclinical and clinical studies aimed at broadening indications and optimizing scaffold designs for various tissue repair needs.

Under the leadership of Chief Executive Officer Craig Singhaus and a management team with deep experience in medical device innovation and commercialization, TELA Bio is committed to transforming soft tissue repair by delivering biomaterial therapies that address unmet clinical needs. The company maintains a collaborative environment with key opinion leaders and academic institutions to drive scientific validation and expand the evidence base for its product platform.